AlitheaGenomics

Alithea Genomics develops high-throughput transcriptomics solutions for research and biomarker discovery, offering proprietary RNA sequencing kits and services that enable scalable, cost-effective gene expression profiling. The company is the home of three core technology platforms under the MERCURIUS brand: DRUG-seq (extraction-free, high-throughput bulk RNA-seq directly from cells without RNA isolation, enabling profiling of thousands of compounds or conditions in a single experiment for pre-clinical drug discovery, hit identification, mechanism of action mapping, off-target prediction, and early toxicity signaling), BRB-seq (massively multiplexed, cost-effective bulk RNA-seq on purified RNA from eukaryotic cells, blood, or plants for scalable gene expression studies with up to 384 library preps in a single tube), and FLASH-seq (full-length, plate-based single-cell RNA-seq delivering ultra-sensitive detection of rare or low-input cells with automation-friendly workflows). Alithea offers these technologies as both kits and services across diverse sample types including cells and cell lines, organoids and spheroids, purified RNA, and blood RNA. The company recently launched the MERCURIUS 1536 DRUG-seq kit in early access, bringing whole-transcriptome profiling to 1536-well compound screening scale for AI-ready perturbation datasets. Alithea serves pharma, biotech and CROs (transcriptomic screening for drug discovery), toxicology and safety testing, mechanism-based discovery, AI-powered screening, agrochemicals and cosmetics, and academic research, with over 100 labs using its platforms worldwide, 50+ publications, and over 1 million full transcriptomes profiled. Founded in 2020 and headquartered in Lausanne, Switzerland, with US operations in Frederick, Maryland, Alithea Genomics has raised approximately $8.1 million in a Seed round backed by Novalis Biotech, TechU, Venture Kick, FIT, Zurcher Kantonalbank, and Startup days.